PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial production. Its core businesses include: a rationally designed building blocks collection, supplying from discovery, to development and commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates and APIs for drug development and commercial. Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of novel building blocks. The team has generated a large and unique collection of high-quality and diverse building blocks, which are increasingly adopted by drug hunters to enrich the structure options, improve compound quality, expand patent space and eventually accelerate drug discovery projects. Following the new molecules advancing from discovery to development, and into the market, the company is now committed to a more comprehensive and long-term service to valued customers. On one hand, PharmaBlock has been strengthening process R&D capabilities and expanding manufacturing capacity to secure the sustainable supply of building blocks. Furthermore, the company is providing development and manufacturing solutions of RSMs, key intermediates and APIs, leveraging the accumulated chemistry expertise, along with extensive know-hows in process R&D, analytical R&D, manufacturing and regulatory affairs, etc. To further realize safe, efficient and green process, PharmaBlock has developed an advanced chemistry and engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, and biocatalysis etc. The technology platform has enabled more innovative solutions, with shortened lead times and reduced overall costs of development and manufacturing projects. PharmaBlock set R&D centers in both Nanjing, China, and Pennsylvania, United States. It has two manufacturing sites at Zhejiang and Shandong Provinces in China, with around 250 m3 combined reactor volume, ranging from 200L to 6,300L of reactor size. Over the past years, PharmaBlock has partnered with almost all the top 20 pharmaceutical companies, and hundreds of small to medium-sized biotechs around the world. Our ever changing mission is to support clients to accelerate drug discovery and development, and move the new molecules to commercial.
Year Established: 2006
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Business Type: Service Provider,Manufacturer
R&D Capacity: Own Brand
Annual Turnover(USD) : More than 99,999,999
Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Subscribe to the latest newsletter of Virtual Expo Connect